Besides, what we need to mention here is that among the 86 clinical samples, in 9 of them, the expression level of DDX31 in the para-cancer tissues was higher than that in the cancer tissues, which we speculated should be caused by the heterogeneity between tumor samples or due to the lack of copy number variation in some tumor patients, we still need to further explore the effect of DDX31 genome level changes on transcriptional level and post-transcriptional translation (Figure 5B; Supplementary Figure S5). This evidence concerns the gene DDX31 and cancer.